Profound thrombocytopenia after primary exposure to eptifibatide

Nicholas B Norgard
Brian T Badgley
University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA

Abstract: Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. A minority of patients given eptifibatide develop acute, profound thrombocytopenia (≤20,000 cells/mm³) within a few hours of receiving the drug. This case report discusses a patient who developed profound thrombocytopenia within hours of receiving eptifibatide for the first time. The Naranjo algorithm classified the likelihood that this patient’s thrombocytopenia was related to eptifibatide as probable. Profound thrombocytopenia is an uncommon but clinically important complication of eptifibatide. This case report emphasizes the importance of monitoring platelet counts routinely at baseline and within 2–6 hours of eptifibatide administration.

Keywords: drug-induced thrombocytopenia, glycoprotein IIb/IIIa antagonists, eptifibatide, thrombocytopenia

Introduction
Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by inhibiting the binding of fibrinogen to activated platelet glycoprotein IIb/IIIa receptors, thereby inhibiting platelet–platelet interaction and thrombus formation. Eptifibatide is part of the antithrombotic therapy used to prevent occlusion of the coronary arteries, thus reducing the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention.1,2 While eptifibatide has significantly improved outcomes in patients undergoing percutaneous coronary intervention and among those presenting with an acute coronary syndrome, a small number of patients given eptifibatide develop acute profound thrombocytopenia (≤20,000 cells/mm³) within a few hours of receiving the drug that can increase the risk of serious bleeding and, in some rare cases, induce thrombosis.3,4 Profound thrombocytopenia is an uncommon but clinically important complication of glycoprotein IIb/IIIa inhibitors. This case report discusses a patient who developed profound thrombocytopenia within hours of first administration of eptifibatide.

Case report
A 42-year-old Caucasian female with no previous history of cardiovascular disease presented to the emergency department with a two-hour history of substernal chest pain that felt crushing in nature and radiated to the left arm and left jaw. Her past medical history included chronic back pain from a road traffic accident and an outpatient tubal ligation. She denied any previous history of blood dyscrasia or thrombocytopenia.
She had smoked two packs of cigarettes per day for the last 28 years. Her family history was significant for her brother having had a stroke. She reported that she was not taking any medications prior to admission. Additionally, she denied any history of a previous hospitalization where she may have received heparin or eptifibatide.

At presentation, her electrocardiogram showed inferior and lateral ST elevation. Initial cardiac markers were creatinine kinase (CK) 407 ng/mL (38–120 ng/mL), CK myoglobin (CK Mb) 2.5 ng/mL (0–3 ng/mL), troponin I < 0.05 ng/mL (0–0.02 ng/mL), and myoglobin 54 ng/mL (0–66 ng/mL). Complete blood count obtained at the time of presentation included a white blood cell count of 8.9 × 10^9/L (normal range 4.1–10.9 × 10^9/L), hemoglobin 14.3 g/dL (12–15.2 g/dL for women), hematocrit 41.6% (37%–46% for women), and platelet count 220 × 10^9/L (140–450 × 10^9/L). A complete metabolic panel drawn at the same time included serum creatinine 0.92 mg/dL, glucose 148 mg/dL (70–100 mg/dL), and electrolytes were within normal limits.

The patient was initiated on aspirin 325 mg po daily, lisinopril 5 mg po daily, metoprolol succinate 50 mg po daily, clopidogrel 300 mg × 1 dose then 75 mg po daily, an intravenous heparin infusion and atorvastatin 80 mg po daily. Within 90 minutes of presentation, she was sent to the cardiac catheterization laboratory for primary percutaneous coronary intervention. Angiography revealed a 100% distal-mid occlusion of the mid left anterior descending coronary artery, and a 40%–50% stenosis in the right coronary artery, a 40%–50% stenosis in the right coronary artery.

Approximately four hours post-eptifibatide initiation, the patient developed a precipitous thrombocytopenia, with her platelet count dropping by over 90% from baseline to 17 × 10^9/L (see Figure 1). A peripheral blood smear showed no signs of platelet clumping, ruling out pseudothrombocytopenia. The rest of her complete blood count at this time included hemoglobin 10.7 g/dL, hematocrit 31.3%, and white blood cell count 6 × 10^9/L. Eptifibatide was subsequently discontinued. The patient’s platelet level reached its nadir (13 × 10^9/L) approximately nine hours post-eptifibatide initiation. The patient’s platelet count gradually climbed, and was 71 × 10^9/L at the time of discharge (approximately 80 hours post-eptifibatide initiation). The patient showed no signs of active bleeding, bruises, ecchymosis, or petechiae during the hospitalization.

One month later, the patient underwent elective percutaneous coronary intervention of her circumflex artery. Her platelet count at the time of the procedure was 142 × 10^9/L. Bivalirudin was used during the percutaneous coronary intervention as an alternative to heparin and eptifibatide. She experienced no reductions in platelet count during the admission and was found to have a platelet count of 180 × 10^9/L at her two-month follow-up clinic visit.

**Discussion**

Drug-induced immune thrombocytopenia is an unpredictable and sometimes serious side effect of many medications, including heparin, quinine, nonsteroidal anti-inflammatory drugs, sulfonamides, and other antibiotics, especially vancomycin, rifampicin, and cephalosporins.6,7 Platelet destruction is usually caused by drug-induced antibodies generated after drug exposure. The predominant pattern is an uneventful first exposure to a drug, then an acute drop in platelet count on re-exposure. Thrombocytopenia induced by the glycoprotein IIb/IIIa antagonist, eptifibatide, does not adhere to this pattern.

There are three clinically approved glycoprotein IIb/IIIa antagonists, ie, abciximab, eptifibatide, and tirofiban. These agents are similar in that they all inhibit platelet aggregation by blocking platelet–fibrinogen interaction via the glycoprotein IIb/IIIa receptor. Abciximab is associated with a higher incidence of thrombocytopenia than eptifibatide and tirofiban, and predominantly more often fits the usual pattern of drug-induced immune thrombocytopenia.8 Thrombocytopenia is seen in about 1% of patients given abciximab for the first time, while acute and more profound thrombocytopenia develops within a few hours in more than 10% of those treated a second time.9–12 Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3 specific for β3 integrin (glycoprotein IIIa).
Most people in the healthy population have pre-existing antibodies to the human Fab portion of abciximab, although this does not appear to play a major role in thrombocytopenia. Patients who develop profound thrombocytopenia develop antibodies specific for the murine 7E3 fragment upon drug exposure.\textsuperscript{13,14} This explains the high incidence of profound thrombocytopenia on re-exposure to abciximab.\textsuperscript{13,14} Although most patients with abciximab-associated thrombocytopenia recover uneventfully, life-threatening bleeding, including intracranial hemorrhage, has been described.\textsuperscript{11,14}

Eptifibatide is a ligand-mimetic drug that competitively inhibits the glycoprotein IIb/IIIa receptor. Eptifibatide binds specifically to the Arg-Gly-Asp recognition site on glycoprotein IIb/IIIa, thereby rendering the glycoprotein IIb/IIIa receptor incapable of binding fibrinogen. The incidence of acute profound thrombocytopenia with eptifibatide has been reported to be 0.2\textsuperscript{%-}1.0\%.\textsuperscript{15} As opposed to abciximab, patients may develop acute profound thrombocytopenia (platelet count <20,000/mm\textsuperscript{3}) upon primary exposure to eptifibatide. Of the 22 reported cases in the literature, only five patients had previous exposure to eptifibatide and three had exposure to abciximab.\textsuperscript{5} The binding of eptifibatide to the glycoprotein IIb/IIIa receptor may induce a conformational change in the receptor, creating ligand-induced binding sites.\textsuperscript{16} Some healthy individuals have strong naturally occurring antibodies that recognize these ligand-induced binding sites and are capable of having severe and sometimes life-threatening thrombocytopenia following drug administration.\textsuperscript{16} These antibodies can be identified in most patients’ blood samples obtained prior to treatment with eptifibatide, affirming that they can be naturally occurring.\textsuperscript{16} A variety of assays have been used to show that most patients developing thrombocytopenia after eptifibatide administration have antibodies that recognize glycoprotein IIb/IIIa occupied by the drug.\textsuperscript{16-18} On the other hand, patients who receive eptifibatide and do not have antibodies of this type do not experience profound thrombocytopenia.\textsuperscript{16} Because thrombocytopenia in patients who have received eptifibatide is usually caused by pre-existing antibodies, pretreatment screening for pre-existing antibodies has been proposed to reduce the incidence of eptifibatide-induced thrombocytopenia, but improvements in antibody detection are needed before this practice becomes routine.\textsuperscript{17}

Treatment with glycoprotein IIb/IIIa antagonists has also been associated with pseudothrombocytopenia, an artifactual finding suspected initially by finding platelet clumping on a blood smear.\textsuperscript{19} It has been shown to account for over one-third of cases of thrombocytopenia during glycoprotein IIb/IIIa inhibitor therapy.\textsuperscript{19} It is of no clinical relevance, but must be ruled out so that glycoprotein IIb/IIIa antagonist therapy
is not unnecessarily discontinued. Pseudothrombocytopenia was ruled out in this patient because there was no platelet clumping observed on peripheral blood smear.

The patient in this report was exposed to several agents during her admission that have been associated with profound thrombocytopenia. Heparin is well known to precipitate thrombocytopenia, but the published literature to date suggests that a previous exposure is required, similar to the reaction seen with heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia type I is characterized by a mild and transient asymptomatic thrombocytopenia (rarely <100,000 platelets/mm³) that develops early (usually within the first two days of starting heparin). Heparin-induced thrombocytopenia type II is immune-mediated and associated with a risk of thrombosis. In patients receiving heparin for the first time, the onset of thrombocytopenia usually occurs 5–10 days after the administration of the heparin. The platelet drop can be seen within hours in patients with pre-existing heparin/platelet factor 4 antibodies from a previous exposure. Our patient’s drop in platelet count was more severe than would be expected with heparin-induced thrombocytopenia type I. Additionally, the patient had no previous exposure to heparin and the timeframe of the decline in platelets does not fit heparin-induced thrombocytopenia type II. This makes it difficult to attribute our patient’s thrombocytopenia to heparin and, due to a low clinical suspicion of heparin-induced thrombocytopenia, serologic tests were not performed.

Thrombotic thrombocytopenic purpura can occur after the initiation of clopidogrel therapy, often within the first two weeks of treatment. Clopidogrel-induced thrombotic thrombocytopenic purpura is characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenia, fever, neurologic manifestations, and renal insufficiency. Other than thrombocytopenia, our patient did not manifest any of the hallmarks of thrombotic thrombocytopenic purpura and only received one 300 mg dose of clopidogrel six hours before the observed drop in platelet count. It is unlikely that clopidogrel played a role in the development of thrombocytopenia in our patient.

The Naranjo algorithm classified the likelihood that the thrombocytopenia was related to eptifibatide as probable. Naranjo scores with heparin and clopidogrel were 1, indicating that these agents were possible, but most likely doubtful, causes of thrombocytopenia in this patient.

Conclusion

Profound thrombocytopenia is an uncommon but clinically important complication of eptifibatide. Thrombocytopenia occurring after first exposure to eptifibatide appears to be explained by the fact that antibodies are naturally present in some individuals. Assays for pretreatment screening for pre-existing antibodies are available, but are not yet established for regular use. This case report emphasizes the importance of monitoring platelet counts routinely at baseline and within 2–6 hours of eptifibatide administration.

Disclosure

The authors report no conflicts of interest in this work.

References